Todos os estudos
RecrutamentoOBSERVACIONAL

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

This is an ongoing study, called ELEVATE, for people living with Acute Hepatic Porphyria (AHP). It's a global project collecting information to better understand this rare condition. Researchers want to see how AHP naturally affects people over time and how doctors are treating it in everyday practice. They are especially interested in gathering real-world information on the safety and effectiveness of approved AHP medications, including a newer one called givosiran. By collecting this information, the study hopes to improve our understanding of AHP and potentially lead to better care in the future. It's not testing a new treatment, but rather observing how existing treatments are used and how the condition develops in the real world.

Em resumo

Status
Recrutamento
Patrocinador
Alnylam Pharmaceuticals
Meta de inscrição
150
Iniciar
26 Apr 2021
Conclusão estimada
31 Dec 2030

Sobre o que é este estudo?

This study, known as ELEVATE, is a bit different from a typical clinical trial. Instead of testing a new medicine, it's a 'registry'. Think of it like a comprehensive patient database specifically designed for people living with Acute Hepatic Porphyria (AHP). The main goal is to build a clearer picture of what it's like to live with AHP today.

Researchers are collecting information from patients over time to understand the 'natural history' of the condition – that means observing how AHP progresses and impacts people's lives without interference. They also want to see how doctors are currently managing AHP in real-world settings, including which treatments are being used and how effective they are. This includes gathering data on new approved treatments for AHP, such as givosiran, to see how they perform in broader use.

By carefully collecting this information from many people across different countries, the study hopes to fill gaps in our understanding of AHP. This knowledge is crucial for doctors and researchers to develop better care strategies, improve diagnoses, and ultimately enhance the quality of life for people with AHP. It helps them understand what works best in practice and where more support or different treatments might be needed.

Pontos principais

  • It's a registry, not a trial of a new drug.
  • Aims to understand AHP's progression and real-world treatments.
  • Includes data on approved medications like givosiran.
  • Open to people with AHP aged 12 and older.
  • Participation involves sharing medical information, not new procedures.
  • Helps improve future AHP care.

Quem pode ser elegível?

To take part in this registry study, you must have a confirmed diagnosis of Acute Hepatic Porphyria (AHP). This diagnosis needs to be made by your doctor. The study is open to both men and women, aged 12 years and older – there's no upper age limit.

You wouldn't be able to join this particular registry if you are currently taking part in another clinical trial where you are receiving an experimental or investigational medicine. This is to ensure the data collected accurately reflects real-world treatment and progression, rather than the effects of a study drug.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Do I have a confirmed diagnosis of Acute Hepatic Porphyria (AHP) from my doctor?
  2. Am I at least 12 years old?
  3. Am I currently NOT taking part in another clinical trial testing an experimental medicine?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this registry, it largely involves allowing your medical information related to your AHP to be collected. This typically means that your doctors will provide de-identified health data to the registry over time. There are no new treatments to take, no special appointments to attend for the study itself, and no new medical procedures you’d need to undergo. The study gathers information from your regular medical care. The length of time you participate would depend on the study design, but registries like this usually follow participants for an extended period to observe long-term trends.

Riscos e benefícios potenciais

The main benefit of participating is contributing important information that could help improve understanding and care for AHP for everyone in the future. Your data, combined with others, helps researchers learn more about how the condition progresses and how treatments work in the real world. There are very few direct risks as you would not be taking any new experimental medications or undergoing additional procedures. Your personal information would be handled confidentially to protect your privacy. You are always free to withdraw from the study at any time without affecting your medical care.

Localizações (30)

  • Clinical Trial Site
    Código postal verificado
    Birmingham, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Gilbert, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    São Francisco, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Baltimore, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Boston, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Minneapolis, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Nova Iorque, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Winston-Salem, Estados Unidos· Concluído
  • Clinical Trial Site
    Código postal verificado
    Oklahoma City, Estados Unidos· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Filadélfia, Estados Unidos· Concluído
  • Clinical Trial Site
    Código postal verificado
    Galveston, United States· Recrutamento
  • Clinical Trial Site
    Código postal verificado
    Salt Lake City, United States· Recrutamento

Perguntas frequentes

What is a patient registry?

A patient registry is like a large collection of health information from people with a specific condition. It helps researchers understand the condition better over time.

Do I have to take new medication?

No, this study is not testing a new medication. It's observing how people with AHP are managed with their usual care and existing approved treatments.

Will my personal details be kept private?

Yes, highly confidential measures are in place to protect your privacy. Your personal identifying information will be kept separate from the data collected for the study.

Por quanto tempo estarei envolvido?

Registries often follow participants for several years to gather long-term information. Your medical team can provide more specific details.

Does taking part affect my regular medical care?

No, participating in this registry will not change your medical care. You will continue to see your own doctors for your AHP treatment as usual.

Como saber mais

Alnylam Clinical Trial Information Line

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "ELEVATE, a Registry of Patients With Acute Hepatic Porphyria…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.